Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic
Trial ID or NCT#
The purpose of this study is to investigate whether an empirically validated treatment for insomnia (CBT-I) administered early in the course of sleep disturbance can prevent insomnia disorder or lessen negative mental health outcomes in the wake of the COVID-19 crisis in adults.
Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms
- - Age 18 years or older - Access to the internet - Subjective complaint of sleep disturbance (ISI ≥10) that began after March 1, 2020 or the COVID-19 Pandemic (self-reported during DUKE Interview) - Lives in the United States
- - Presence of suicidal ideation representing high risk as measured by the Sheehan-Suicide Tracking Scale (S-STS). - Use of medication specifically prescribed for sleep disturbance and unwilling or unable to discontinue more than one week prior to baseline data collection. - Current or lifetime history of bipolar disorder or psychosis - Current substance abuse or dependence - Not able to verbalize understanding of involvement in research and provide written, informed consent - Not fluent or literate in English - Unstable pharmacotherapy for other mental health disorders - Severe impediment to vision, hearing, and/or hand movement, likely to interfere with the ability to complete assessments, or are unable and/or unlikely to follow study protocols - Working rotating shift that overlaps with 2400h
Contact us to find out if this trial is right for you.
Andrea Goldstein-Piekarski, PhD